Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.
View full SUMM profile View Profile
June 18 2019
April 16 2019
April 15 2019
April 03 2019